Clinical trials
Withdrawn Carcinoma, Hepatocellular trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
130 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 6 |
| 2013 | 8 |
| 2014 | 6 |
| 2015 | 13 |
| 2016 | 6 |
| 2017 | 8 |
| 2018 | 11 |
| 2019 | 13 |
| 2020 | 11 |
| 2021 | 4 |
| 2022 | 10 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 130 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 8 |
| National Cancer Institute (NCI) | 5 |
| Guangxi Medical University | 4 |
| M.D. Anderson Cancer Center | 3 |
| Seoul National University Hospital | 3 |
| Shanghai Zhongshan Hospital | 3 |
| Shi Ming | 3 |
| Case Comprehensive Cancer Center | 2 |
| Eli Lilly and Company | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 130 |
| Liver Neoplasms | 23 |
| Cholangiocarcinoma | 6 |
| Hepatitis C | 4 |
| Neoplasm Metastasis | 4 |
| Carcinoma, Renal Cell | 3 |
| Colorectal Neoplasms | 3 |
| Gallbladder Neoplasms | 3 |
| Liver Cirrhosis | 3 |
| Bile Duct Neoplasms | 2 |
Trials
Showing 51 to 75 of 130. Each trial links to its page on Pharma Observatory.
30 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.